• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
      • Overview
      • Join NACs Network
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Consultation on the availability of piperacillin and ticarcillin without inhibitors.

EUCAST is considering removing breakpoints for piperacillin without tazobactam and/or ticarcillin without clavulanic acid but only if these agents are no longer used. If you in your country are still using either or both of these agents without an inhibitor, please inform the EUCAST Scientific…

Get to know more

Publications and Presentations

Publications and Presentations Recent publication: How to interpret MICs of amphotericin B, echinocandins and flucytosine against Candida auris ( Candidozyma auris ) according to the newly established European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints Maiken Cavling…

Get to know more

Br. melitensis and B. anthracis - MIC and zone diameter distributions available

EUCAST will during 2023, based on the work of theEMERGE AST Working Group , strive to publish clinical breakpoints and disk diffusion correlates for Brucella melitensis and Bacillus anthracis. Through the joint effort of the group and EUCAST, MIC and zone diameter distributions are now available .…

Get to know more

Correlation between MIC and disk diffusion for anaerobic bacteria. Updated file with more antibiotics.

The correlation between MIC and inhibition zone diameters in disk diffusion is excellent when utilizing species specific breakpoints for anaerobic species and species groups, in the same way EUCAST has dealt with facultative aerobic bacteria over the last 25 years. In this presentation the EUCAST…

Get to know more

Breakpoint table v. 11: a mistake in the Staphylococcus spp tab.

There is a mistake in the EUCAST breakpoint table v 11.0 where, in the Staphylococcus spp tab, the fluroquinolone section, the footnote C should read:Isolates categorised as susceptible to norfloxacin can be reported susceptible (S) to moxifloxacin and "susceptible increased exposure" (I) to…

Get to know more

MIC distributions and ECOFFs

MIC distributions and ECOFFs ECOFFs can be used to detect isolates with resistance mechanisms and thus for surveillance of resistance development. For many or most species and agents, clinical breakpoints and ECOFFs will coincide but for some species and agents, isolates with low-level resistance…

Get to know more

Proposed change of breakpoints for aminopenicillins in enterococci

Proposed change of breakpoints for aminopenicillins in enterococci (consultation period 7 May - 14 June, 2024). Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Comments not…

Get to know more

EUCAST Online seminars on 3 (breakpoint table 2022) and 9 December (disk diffusion of anaerobes), 2021

EUCAST invites toonline seminars on the 3 and 9 December - each seminaris open at 8-9 AM, 1-2 PM and 4-5PM to facilitate participationfor colleagues in different time zones. As always, seminars are free of charge. Links are available here. 3 of December: What is new in breakpoint table v12.0. 9 of…

Get to know more

Consultation on Breakpoints for C. diphtheriae and C. ulcerans.

The EUCAST general consultation on Corynebacterium diphtheriae and C. ulcerans is open for comments 9 July - 11 September, 2022. Together with specialists in Paris and Munich, 200 isolates of each species were investigated with broth microdilution MIC determination and disk diffusion as a backdrop…

Get to know more

Cefiderocol: EUCAST has evaluated (August 2022) commercially available tests and all have problems with accuracy, reproducibility, bias and/or for some, with skipped wells.

EUCAST has evaluated (August 2022) commercially available tests and all have problems with accuracy, reproducibility, bias and/or for some, with skipped wells. For this reason, it is difficult to resolve the susceptibility interpretation of isolates in the ATU (area of technical uncertainty) in…

Get to know more
Show more results
© EUCAST 2026. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies